Sangamo Therapeutics (SGMO) is a $650 million dollar market cap company focused on gene and cell therapies, including conducting the first-ever genome editing studies in clinical trials. The company uses gene therapy, genome editing, cell therapy, and gene regulation techniques to develop novel therapies. In gene therapy, attenuated Adeno-Associated Viral ((NYSE:AAV)) delivery systems are employed to carry functional gene copies to patients suffering from an ineffective or absent protein causing a disease state, such as in Hemophilia A (in collaboration with Pfizer (NYSE:PFE). The company is developing genome editing technologies for Hemophilia B and various lysosomal storage disorders, employing zinc finger nucleases (ZFN) to knock out harmful, defective, or unwanted proteins and also to insert helpful donor genes. The company is also utilizing gene editing and cell therapy techniques (T cell and stem cell) to treat HIV, and is partnering with Bioverativ (BIVV) to develop stem cell treatments for beta-thalassemia and sickle cell disease. Cell therapy can be used in conjunction with ZFN technology after harvesting afflicted cells, treating, testing for desired effects, cultured, then reinfused into the patient. Because ZFPs are the most common DNA binding motif in transcription factors of eukaryotic systems, gene repression or activation systems can be generated. SGMO is pursuing in central nervous system afflictions such as Huntington's Disease (in collaboration with Shire (SHPG)), by using specific gene repression of mutant disfunctional HTT gene but leaving functional gene products unchanged. Sangamo is attacking Alzheimer's and various tauopathies utilizing the same approaches. The company is also advancing non-therapeutic technologies with Sigma-Aldrich Corporation and Dow AgroScience.
Pfizer is a leading developer of AAV-based technologies. SGMO and Pfizer's collaboration in hemophilia A in May 2017 to develop AAV-based drug candidate gene therapy SB-525, one of Sangamo's four lead drug candidates, has received orphan drug status and fast track from FDA and EMA, and was perceived by the market as a big boost of confidence for Sangamo. The stock is up over 100% since the announcement. Pfizer made an initial payment of $70 million with up to $475 million in potential milestones, with $175 million potential for additional gene therapies if opted by Pfizer. Mikael Dolsten, president of worldwide research and development at Pfizer, stated, "We believe SB-525 has the potential to be a best-in-class therapy" that could provide stability to patients "with a single administration treatment." SGMO ZFN technology had recently been overshadowed in market sentiment by next-generation genome-editing technologies such as CRISPR prior to the announcement.
The company announced in the first quarter 2017 that it had received orphan drug designation (ODD, previously attained) and fast track designation from FDA for genome editing treatment SB-FIX for Hemophilia B. SGMO also progressed in lysosomal disorders by obtaining Rare Pediatric Disease Designation for in vivo genome editing treatment SB-318 for MPS I. In this disorder a deficiency in alpha-L iduronidase results in toxic buildup of glycosaminoglycans. According to the 2017 first quarterly report, "a sponsor who receives approval for a new drug application or biologics license application may be eligible to receive a voucher for a priority review of a subsequent marketing application for a different product. The voucher may be used by the sponsor or sold or transferred." SB-318 had also previously received ODD. The company also received ODD and Rare Pediatric Disease Designation for in vivo genome editing treatment SB-913 for MPS II (Hunter's disease). In this disorder, iduronate-2-sulfatase deficiency results in the buildup of glycosaminoglycans as well.
Sangamo's ZFN-mediated genome editing program for sickle cell disease and beta-thalassemia hemoglobinopathies transferred to Bioverativ in November of 2016, as part of a 2014 deal with Biogen. Bioverativ spun off from Biogen in early 2017 as a separate entity with specific experts to handle transformation of therapies for these rare diseases. Experts in related blood diseases hemophilia A and B medications will oversee sales and marketing of its lead products ELOCTATE and ALPROLIX respectively, as part of the responsibilities of the company.
Sangamo is using ZFN-mediated genome editing in the HIV space as well. Sangamo Therapeutics' approach inserts a naturally occurring human mutation which renders individuals largely resistant to HIV into T-cells and is monitoring patients in an open label phase 2 trial. Sangamo's SB-728-T HIV drug candidate targets the most common form of HIV. A Phase 1/2 clinical trial is also being conducted to evaluate safety and efficacy of its stem cell candidate, SB-728-HSPC, in HIV patients.
At the preclinical level, in vitro human culture and animal model data demonstrated significant reduction of tau mRNA and tau protein expression using ZFP transcription factor-mediated gene regulation technology. Results from the laboratory studies were presented at the 13th International Conference on Alzheimer's & Parkinson's Diseases.
Sangamo recently raised approximately $72 million in a public offering June 21, 2017, at $7.25 per share. An analyst at Jefferies was recently impressed by the company's presentation at a conference, and set a $17 per share price target on the SGMO shares. The company says it plans to use the funds to develop genomic therapy product candidates and potentially acquire complementary businesses, technologies, or licenses. Additionally the analyst said that this stock can serve as a financial investment hedge against the emerging gene-editing technology of CRISPR.
The gene editing and cell therapy spaces are definitely unproven to some extent and risky. There is also competitive risk in that this company is going up against some of the best regarded technologies in a tough field of gene and cell therapies that are possibly further advanced, including CRISPR. However, the risks are higher for Alzheimer's and HIV than for more straight-forward indications such as Hemophilia A. Pfizer's $70 million stamp of approval should reinforce that argument. Given the high quality partnerships for SGMO and relatively diverse pipeline, the reward to risk ratio should be adequate for a long position at these prices. The company is still in early to mid-stage trials, but a breakthrough in a rare or fatal indication could be an inflection point for the stock.
As of end Quarter one the company estimated $132 million in cash, taken with the recent offering of ~$70 million and estimated quarterly burn rate of ~$30 million leaves about $170 million in cash. This is a significant cash runway but given the immaturity of the clinical trial pipeline it is hard to predict if more dilution will be necessary in coming years. With only about $3 million in quarterly revenues trickling in its doubtful that the company can go without diluting if something were to go wrong. However, with its nice strategic partnerships and potential milestones from Pfizer, if things go well in the Hemophilia A project the company could near a cash neutral position within a couple of years.
Strong Bio regards this stock as a great watchlist stock, with intent to invest on significant pullbacks over time. Future clinical trial updates that indicate novel and robust responses could indicate FDA breakthrough therapy designation-worthy therapies. Of particular interest to Strong Bio are the projects of Alzheimers, HIV and cancer, as they have potential to show strong benefit in large markets. However, waiting too long might put investors in a "pay over the top" position as the more lead project Hemophilia A, B, and HIV projects progress. Strong Bio targets an entry in the $6.75 range.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Read more here:
Is Sangamo Therapeutics Pointing Toward Success? - Seeking Alpha
- Cell Therapy Basics - February 21st, 2024
- FDA Approves Amtagvi, First Cell Therapy for Skin Cancer - BioPharm International - February 21st, 2024
- Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial - PR Newswire - February 21st, 2024
- Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m - PMLiVE - February 21st, 2024
- Bridging Therapy With CAR T-Cell Therapy in LBCL - OncLive - February 21st, 2024
- FDA approves first cell therapy to treat aggressive forms of melanoma - NPR - February 21st, 2024
- Iovance, with approval of 'TIL' cell therapy, readies for complex launch - Yahoo Finance - February 21st, 2024
- Cancer treatment: FDA approves type of cell therapy for patients with late-stage melanoma - FOX 26 Houston - February 21st, 2024
- Pharmalittle: We're reading about weight loss drugs, a cell therapy for melanoma, and more - STAT - February 21st, 2024
- On heels of cancer cell therapy win, Peninsula biotech looks to raise $211M - San Francisco Business Times - The Business Journals - February 21st, 2024
- FDA approves cell therapy to treat melanoma - FOX 26 Houston - February 21st, 2024
- Toddler Beats Childhood Leukemia After Car T-Cell Therapy - City of Hope - February 21st, 2024
- FDA Approves First One-time Cell Therapy for a Solid Tumor - BioSpace - February 21st, 2024
- Iovance wins FDA approval for cell therapy - BioProcess Insider - BioProcess Insider - February 21st, 2024
- FDA Approves Iovance Cancer Treatment, the First Cell Therapy for a Solid Tumor - MedCity News - February 21st, 2024
- Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas - Medical Xpress - February 21st, 2024
- Reinforcing Cell Therapy with Microfluidic Cell Sorting - RegMedNet - February 21st, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 21st, 2024
- Understanding CAR T-Cell Therapy: Balancing the Risks and Benefits - Medriva - February 21st, 2024
- Keeping Track: Iovance's Amtaqvi Approval Brings T Cell Therapy To Solid Tumors - Pink Sheet - February 21st, 2024
- Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be ... - Yahoo Finance - February 21st, 2024
- What is CAR-T cell therapy, used for cancer treatment? Experts explain - India Today - India Today - February 21st, 2024
- UPDATE: 2seventy splits once more, sending cell therapy pipeline to Regeneron in 'dramatic' change - FierceBiotech - January 31st, 2024
- Revolutionary CAR T-cell therapy shows promise in reversing age-related metabolic dysfunction - News-Medical.Net - January 31st, 2024
- BioCardia Pivots to Biomarker Strategy to Prove Heart Failure Cell Therapy Benefits - precisionmedicineonline.com - January 31st, 2024
- Sequencing With CAR T-Cell Therapy for LBCL - OncLive - January 31st, 2024
- Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy ... - pnas.org - January 31st, 2024
- Regeneron to acquire 2seventy's cell therapy pipeline - Yahoo Finance - January 31st, 2024
- Trial of cell-based therapy CK08031 finishes dosing 1st patients - ALS News Today - January 31st, 2024
- Exploring Gene and Cell Therapy Integration in Pharmacies - PharmaNewsIntel - January 31st, 2024
- HBS Alumna Fighting Cancer with a Novel Cell Therapy - MBA - hbs.edu - January 31st, 2024
- YUHS partners with KURE.AI Therapeutics for cell therapy development - KBR - January 31st, 2024
- Global CAR-T Cell Therapy Market Report 2024-2034: Accelerated Growth Fueled by Intensive R&D, Growing Medical ... - Yahoo Finance - January 31st, 2024
- Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy ... - PR Newswire - January 31st, 2024
- A new chapter in cell therapy: engineered B cells reach the clinic for the first time - Labiotech.eu - January 31st, 2024
- Harnessing the Dark Genome: New Approach Greatly Improves Cancer T-Cell Therapy - SciTechDaily - January 31st, 2024
- Cell therapies | Harvard Stem Cell Institute (HSCI) - November 16th, 2023
- Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological... - April 15th, 2023
- Basal Cell Carcinoma Treatment - The Skin Cancer Foundation - January 4th, 2023
- Adoptive Cell Therapy - Cancer Research Institute (CRI) - December 27th, 2022
- National Medical Commission prohibits use of stem cell therapy to treat patients with autism - Hindustan Times - December 18th, 2022
- Tumor buster - where will the CAR-T cell therapy missile go? - December 18th, 2022
- Gilead lands new cell therapy for Kite in $225M Arcellx deal, providing global scale for future J&J-Legend showdown - FierceBiotech - December 10th, 2022
- Non-Small Cell Lung Cancer Treatment (PDQ)Patient Version - November 24th, 2022
- CAR-T Cell Therapy Program - Frequently asked questions - November 24th, 2022
- EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell... - November 24th, 2022
- Radiation Therapy for Non-Small Cell Lung Cancer - November 6th, 2022
- AvenCell to Present New Data from Lead Universal CAR T Cell Therapy Program at 64th American Society of Hematology Annual Meeting and Exposition -... - November 6th, 2022
- Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials - MarketWatch - November 6th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 6th, 2022
- Photodynamic Therapy to Treat Cancer - NCI - October 29th, 2022
- Researchers at University Hospitals create a breakthrough in CAR-T cell therapy for cancer patients - News 5 Cleveland WEWS - October 29th, 2022
- Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th... - October 29th, 2022
- Gilead, working to improve cancer cell therapy, partners with California startup - BioPharma Dive - October 21st, 2022
- Allogene starts first pivotal trials of an 'off-the-shelf' cell therapy for cancer - BioPharma Dive - October 13th, 2022
- Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers - Business Wire - October 13th, 2022
- CAR T-cell Therapy Market Riding on the Wave of Growth and will Grow at a CAGR of 30.6% to 2031 | TMR Study - GlobeNewswire - October 13th, 2022
- Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors - PR Newswire - October 13th, 2022
- Cell Therapy Technologies Market Expected to Reach US ~$12.27 Billion and CAGR 14.5% by 2030 Polaris Market Research - Digital Journal - October 13th, 2022
- Early Data on GPRC5D-Directed CAR T-Cell Therapy Open Doors for New Myeloma Treatment Strategies - Precision Oncology News - October 13th, 2022
- BREAKTHROUGH TECHNOLOGY FOR IPS-DERIVED CELL THERAPIES TURNED INTO GMP PLATFORM BY TREEFROG THERAPEUTICS & INVETECH - PR Newswire - October 13th, 2022
- Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases -... - October 13th, 2022
- Breast cancer treatment: These targeted therapies are a ray of hope for patients - Health shots - October 13th, 2022
- Two-Year Clinical Data for DiscGenics's Progenitor Cell Therapy for Lumbar Disc Degeneration to Be Presented at NASS 2022 - PR Newswire - October 13th, 2022
- Mayo Clinic Minute: What is CAR-T cell therapy? - Finger Lakes Times - October 13th, 2022
- Gamma Biosciences and Lonza Collaborate to Co-develop Reagents for Clinical Cell Selection in the Cocoon Platform USA - English - USA - English - PR... - October 13th, 2022
- Merck and Moderna Move Forward with Personalized Cancer Vaccine - BioSpace - October 13th, 2022
- First Patient With B-NHL or CLL Treated With MB-106 in Phase 1/2 Study - Targeted Oncology - October 13th, 2022
- MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022 - Yahoo Finance - October 13th, 2022
- Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy - GlobeNewswire - October 13th, 2022
- Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy -... - October 13th, 2022
- Integrating CAR T-Cell Therapy Into Community Oncology Practices - Targeted Oncology - October 4th, 2022
- About CAR-T cell therapy - Mayo Clinic - October 4th, 2022
- Autologous immune-cell therapy, practiced in Japan, now helping Vinmec Hospital, treat cancer patients in Hanoi, Vietnam, after technology transfer by... - October 4th, 2022
- Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B... - October 4th, 2022
- Regenerative Spine and Pain Institute: Treating Pain with PRP and Stem Cell Therapy - Community News - October 4th, 2022
- City of Hope To Accelerate Immunotherapy Research And Treatment Innovation with $15 Million Gift From Ted Schwartz Family - City of Hope - October 4th, 2022
- Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel - Business Wire - October 4th, 2022
- Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors - Yahoo Finance - October 4th, 2022
- SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ AAC Platform's Potential as an Effective Red Blood Cell-Derived Immunotherapy -... - October 4th, 2022